GleamWall
中文EN

ELDN Eledon Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1404281 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-6.6%
TTM EPS YoY-586.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-257.1%
ROA-71.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets34.5%
Debt / equity0.00x
Current ratio6.30x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.92x
Accruals ratio-5.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$66.27M$51.96M
SG&A expense$16.98M$18.61M
Pretax income-$45.58M-$35.75M
Income tax$35,000$431,000
Net income-$45.62M-$36.18M
EPS (basic)-0.52-0.66
EPS (diluted)-0.52-0.66
Weighted avg. shares (diluted)81.84M48.54M
Balance sheet
Cash & equivalents$22.81M$20.55M
Short-term investments$110.53M$119.63M
Current assets$135.69M$143.73M
Total assets$169.01M$177.41M
Current liabilities$18.34M$11.58M
Total liabilities$32.23M$59.27M
Shareholders' equity$81.08M$62.45M
Shares outstanding75.43M59.79M
Cash flow statement
Operating cash flow-$62.34M-$47.27M
Investing cash flow$10.79M-$70.31M
Financing cash flow$53.81M$133.52M
Stock-based compensation$10.45M$13.12M

Free plan shows the latest 2 periods; Pro shows all 14 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.